Twist Bioscience Launches Synthetic RNA Positive Controls For SARS-CoV-2 Encapsulated Minicapsules


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


Twist Bioscience Corporation (NASDAQ:TWST) has launched specific synthetic RNA positive controls for SARS-CoV-2 encapsulated in stainless steel mini capsules that Imagene SA provided. 

  • The airtight mini capsules provide a stable environment for the RNA controls, allowing cost-effective shipping and storage at room temperature of fragile RNA for an extended period. 
  • In particular, the product enhancement will enable Twist to serve customers in regions that do not have an effective cold chain system or easy access to ultra-cold storage and also allow the use of the controls in point of care settings.
  • This is an expansion of Twist's first agreement with Imagene in July 2019 to use Imagene's DNAshell technology for long-term storage of digital data encoded in DNA. Using Imagene's encapsulation technology, Twist now can ship and store both DNA and RNA products for long periods. 
  • The Twist synthetic controls are designed based on specific SARS-CoV-2 variants, cover the full viral genome, and are sequence-verified. 
  • Price Action: TWST shares are down 4.81% at $48.14 during the market session on the last check Monday.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsHealth CareContractsMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusDiagnostics